Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "NIH"

74 News Found

Mandaviya chairs 7th meeting of Central Institute Body of AIIMS and Chintan Shivir at NIHFW, Delhi
News | July 31, 2023

Mandaviya chairs 7th meeting of Central Institute Body of AIIMS and Chintan Shivir at NIHFW, Delhi

Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS


NIHR addresses research in surgery in India
News | September 28, 2022

NIHR addresses research in surgery in India

The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit


WHO and MPP announce agreement with NIH for Covid-19 health technologies
Public Health | May 13, 2022

WHO and MPP announce agreement with NIH for Covid-19 health technologies

The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries


Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA
Biotech | March 16, 2022

Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA

The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process


WHO and MPP welcome NIH’s offer of COVID-19 health technologies to C-TAP
News | March 04, 2022

WHO and MPP welcome NIH’s offer of COVID-19 health technologies to C-TAP

Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements


Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


NIH grants in-principle accreditation to Advanced Enzymes supplements
Healthcare | October 20, 2021

NIH grants in-principle accreditation to Advanced Enzymes supplements

The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness


NIPER, Raebareli signs technology transfer pact with Lofty Laboratories
Policy | May 09, 2026

NIPER, Raebareli signs technology transfer pact with Lofty Laboratories

Academia-industry partnership to promote indigenous technology commercialization in biotech sector


Bayer pushes stroke prevention drug forward in China as regulators accept key filing
News | May 02, 2026

Bayer pushes stroke prevention drug forward in China as regulators accept key filing

Stroke is the second-leading cause of death and the third-leading cause of disability worldwide


Bayer flags major Phase III results for stroke prevention drug asundexian
Clinical Trials | April 17, 2026

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy